A clinical trial to study the effects of the drug capsule dabeedul ward in patients with non alcoholic fatty liver disease
- Conditions
- Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified
- Registration Number
- CTRI/2023/11/059554
- Lead Sponsor
- Jamia Hamdard
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Age 18-60 years
Patient of all genders
Patient willing to participate and sign the written informed consent
Patient diagnosed as having fatty liver based on the ultrasonography report
Patients with/ without clinical signs and symptoms
Age below 18 and above 60 years
Use of alcohol or any other drug abuse
Patients diagnosed with any coexisting liver disease
Pregnant and lactating women
Patients suffering with Hypertension, CKD, CAD, CLD or uncontrolled DM,thyroid disorder.
Patient having immune-compromised status.
Patient using lipid lowering drugs or dietary supplements within the last 3 weeks.
Oral contraceptives & corticosteroids.
Neurological disorders like epilepsy or psychiatric disorders
Patient having history of Pancreatitis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Abdominal ultrasound - <br/ ><br>We will assess steatotic liver changes by Quantitative <br/ ><br>Tissue attenuation measurement with S-Shearwave <br/ ><br>Imaging Technique before and after drug administrationTimepoint: From baseline to 12 weeks <br/ ><br>
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.